Timber Pharmaceuticals, Inc.
TMBR
TMBR was delisted on the 28th of November, 2023.
17 hedge funds and large institutions have $1.03M invested in Timber Pharmaceuticals, Inc. in 2021 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 4 increasing their positions, 1 reducing their positions, and 7 closing their positions.
300% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 1
0% more funds holding
Funds holding: 17 → 17 (0)
0% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 7
45% less capital invested
Capital invested by funds: $1.89M → $1.03M (-$857K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$359K |
| 2 |
VF
Virtu Financial
New York
|
+$73.8K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$53.5K |
| 4 |
Jane Street
New York
|
+$30.6K |
| 5 |
Two Sigma Advisers
New York
|
+$25.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$123K |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$96K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$61K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$59K |
| 5 |
Goldman Sachs
New York
|
-$22K |
TMBR Hedge Fund Activity: Q4 2021 in Review
17 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in Timber Pharmaceuticals, Inc. (TMBR) for Q4 2021, worth a combined $1.03M — down 45% from $1.89M a quarter earlier.
Fund positioning in TMBR was balanced in Q4 2021: 7 funds opened new positions, 7 closed out, 4 added to existing stakes and 1 trimmed.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $359K. The largest seller was T. Rowe Price Associates, exiting entirely with an estimated $123K sold.
- 17 institutional investors held Timber Pharmaceuticals, Inc. (TMBR) as of Q4 2021, unchanged from Q3 2021.
- Funds reported $1.03M of Timber Pharmaceuticals, Inc. stock for Q4 2021, down 45% quarter-over-quarter.
- 7 funds opened new Timber Pharmaceuticals, Inc. positions in Q4 2021 and 7 closed out, a net change of 0 holders.
- The largest Timber Pharmaceuticals, Inc. buyer in Q4 2021 was Renaissance Technologies, an estimated $359K added.
- The largest Timber Pharmaceuticals, Inc. seller in Q4 2021 was T. Rowe Price Associates, an estimated $123K sold.
Based on aggregated 13F filings for Q4 2021.